Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image
- PMID: 16093982
- DOI: 10.1097/01.ju.0000172567.09442.b0
Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image
Abstract
Purpose: We report the surgical technique and results of epididymal sparing bilateral simple orchiectomy as an esthetic alternative to standard bilateral simple orchiectomy and luteinizing hormone releasing hormone (LH-RH) agonist injection therapy in patients with prostate cancer.
Materials and methods: The study included 91 consecutive epididymal sparing bilateral simple orchiectomy (BSO) procedures that were performed at the Atlanta Veterans Affairs Medical Center during a 25-month period. All patients had pathologically confirmed prostate cancer. A total of 52 patients (57.1%) were receiving LH-RH agonist therapy prior to the procedure and the remaining 39 (42.9%) were not. All procedures were performed in an outpatient clinic setting using spermatic cord anesthesia block as the only method of anesthesia. In the 52 patients who were on LH-RH agonist therapy prior to the procedure the overall impression/satisfaction with the procedure was evaluated using a questionnaire.
Results: All 91 procedures were performed at the urology outpatient clinic using local anesthesia. Mean patient age was 74.2 years (range 44 to 86). Mean serum prostate specific antigen was 58.9 ng/ml. The mean time required to perform the spermatic cord anesthesia block was 3.9 minutes (range 2 to 6) and the volume of anesthetic solution was 18.9 ml per case (range 10 to 32). Despite significant difference in testicular size between patients receiving and not receiving LH/RH agonists there were no differences in anesthesia time or anesthetic volume (3.9 and 3.9 minutes, p = 0.97, and 18.6 and 19.4 ml, respectively, p = 0.47). Mean operative time for BSO excluding anesthesia time was 36.9 minutes (range 18 to 70). Mean operative time was similar in patients receiving and not receiving LH-RH agonists (36.2 and 37.8 minutes, respectively, p = 0.39). The procedure was well tolerated, as judged by the mean intraoperative pain score during BSO of 0.2 (range 0 to 3). The majority of patients (76 or 83.5%) were pain-free during the procedure. Pain scores were similar in patients who were and were not receiving LH-RH agonists during BSO (p = 0.97). There were no adverse events. Followup data were available on 26 of the 52 patients who were receiving LH-RH agonist therapy prior to the procedure. Of them 96.2% were satisfied with the results and 84.6% preferred the procedure over medical castration therapy with LH-RH agonist therapy.
Conclusions: Epididymal sparing bilateral simple orchiectomy is a simple and safe procedure that can be conveniently performed in an outpatient clinic setting using pure local anesthesia. Preservation of the epididymis and subsequent epididymoplasty is effective for maintaining the esthetic appearance of the scrotum and patient satisfaction. The procedure offers patients the convenience of 1-time surgical therapy over lifelong medical injection therapy at a significantly lower cost and without significantly compromising the esthetic appearance of the scrotum.
Comment in
-
Re: Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.J Urol. 2006 May;175(5):1966-7; author reply 1967. doi: 10.1016/S0022-5347(05)00964-X. J Urol. 2006. PMID: 16600812 No abstract available.
Similar articles
-
The fate of the medically castrated testis: expectation versus reality.J Urol. 2004 Sep;172(3):1042-4. doi: 10.1097/01.ju.0000135831.19857.5c. J Urol. 2004. PMID: 15311033
-
Spermatic cord anesthesia block for scrotal procedures in outpatient clinic setting.J Urol. 2004 Dec;172(6 Pt 1):2358-61. doi: 10.1097/01.ju.0000144544.43148.10. J Urol. 2004. PMID: 15538267
-
Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.J Urol. 2007 Jun;177(6):2132-5; discussion 2135. doi: 10.1016/j.juro.2007.01.157. J Urol. 2007. PMID: 17509298 Clinical Trial.
-
Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.Clin Ther. 2006 Oct;28(10):1485-508. doi: 10.1016/j.clinthera.2006.10.018. Clin Ther. 2006. PMID: 17157109 Review.
-
[Management of a hormone dependent cancer with endocrine therapy--prostate cancer].Gan To Kagaku Ryoho. 2001 Jul;28(7):917-26. Gan To Kagaku Ryoho. 2001. PMID: 11478140 Review. Japanese.
Cited by
-
Can Subepididymal Orchiectomy Re-emerge as the Treatment of Choice in Patients with Advanced Prostatic Carcinoma?Indian J Surg. 2015 Feb;77(1):23-7. doi: 10.1007/s12262-012-0741-z. Epub 2012 Sep 18. Indian J Surg. 2015. PMID: 25829707 Free PMC article.
-
Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review.Front Endocrinol (Lausanne). 2023 Feb 6;14:1131715. doi: 10.3389/fendo.2023.1131715. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36814583 Free PMC article.
-
Prospective randomised controlled trial comparing sub-epididymal orchiectomy versus conventional orchiectomy in metastatic carcinoma of prostate.Indian J Surg. 2011 Jun;73(3):175-7. doi: 10.1007/s12262-010-0207-0. Epub 2011 Feb 1. Indian J Surg. 2011. PMID: 22654325 Free PMC article.
-
Simple and Epididymal-Sparing Orchiectomy for Surgical Castration in Stage IV Prostate Cancer.Ochsner J. 2024 Fall;24(3):171-178. doi: 10.31486/toj.24.0013. Ochsner J. 2024. PMID: 39280863 Free PMC article.
-
Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy.Prostate Int. 2015 Dec;3(4):123-6. doi: 10.1016/j.prnil.2015.10.015. Epub 2015 Oct 20. Prostate Int. 2015. PMID: 26779458 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical